Innovation through proprietary technology platforms

Our Activities

Innovation for the future

Product Pipeline

Our entry to the world


Operational excellence


Our new manufacturing site in Madrid


Direct presence in Spain & Portugal


Our Activities

“Our activities are defined by constant research and development. We innovate with a focus on our proprietary technology platforms. Our own EU and FDA approved manufacturing facilities in Spain and the US make us flexible and efficient”

Alberto Bueno, CEO


Our strength

Innovation is the fuel that drives our business. Whether through projects stemming from the company’s in-house R&D or by partnering with public and private research groups, our research is focused around three therapeutic areas: Otolaryngology, Ophthalmology and Gastroenterology. All products developed by Salvat share a common goal, to provide innovative solutions to improve people’s quality of life.

Additionally, we offer our R&D services to other companies interested in the potential of our proprietary technologies and the skills of our internal development team. We offer contract development services for products inside and outside our core therapeutic areas.

Gastroenterology has been one of Salvat’s areas of focus since our foundation. Our Orally Dispersible Tablets (ODT) are an innovative technology that has been licensed-out worldwide. Salvat’s Multiparticulate platform is a technology platform with the capability of providing a drug delivery toolbox with “on demand” oral drug release profiles through the digestive tract. The result of our R&D in Gastroenterology is present in Monolitum® Flas, the leading lansoprazole brand in Spain. We also have Levogastrol for dysmotility-like functional dyspepsia and Nutira, an innovative line of products for Lactose intolerance.

Salvat is a world leader in otolaryngology. Our constant innovation in the field has allowed us to lead the Spanish market and to achieve constant growth in other geographies.
Cetraxal ®, Otovel®, Tinnitan® and Saletego® are a few of the many specialty brands we’ve built with an exclusive focus on otolaryngology.

Taking advantage of our existing technology platforms, in 2010 we ventured into ophthalmology. We use Blow-Fill-Seal technology for the development of sterile, preservative free ophthalmic solutions that improve convenience and compliance.
Our ophthalmic products include Tebarat®, Cetraflux®, Ursitan® and the umbrella brand Relive®, that includes food supplements, medical devices and drugs for the treatment of dry eye.

New Therapeutic Entities

Product Pipeline

Innovation for the future

We focus our research on three therapeutic areas: otolaryngology, ophthalmology and gastroenterology, but also with an eye on the local OTC market. Our proprietary technology platforms are the core of our innovation. This allows us to develop new formulations and new combinations, which target novel indications with already-known molecules. These are our new therapeutic entities. Our goal is to develop products that improve convenience and compliance, therefore improving the quality of life of our patients.

Bonecure (SVT-1001)

Bonecure is a cell therapy project, in which allogeneic mesenchymal stem cells subjected to a specific pre-differentiation process are used, for the treatment of patients with post-fracture bone consolidation problems. The cells are applied locally by implanting calcium phosphate supports into which the cells have previously been inoculated.


Development of a product in single-dose vials, preservative-free, for the treatment of fungal otitis externa (otomycosis). After approval of the IND by the FDA, phase III clinical trials have begun in USA, Mexico and Europe, which must provide the necessary data for marketing approval, which would constitute the first FDA and European Authorities approved drug for the treatment of otomycosis.


NTE* for the treatment of inflammation and pain that occurs after cataract surgery. The product is innovative in the way that the active principle has never been used by ocular route and is formulated in single-dose vials, preservative-free, and in the form of a nano-emulsion, which facilitates its therapeutic effect and the tolerability of the product.


Single dose vial formulation of a prostaglandin analog for the treatment of open angle glaucoma and ocular hypertension. Its formulation avoids the need to store the product at a low temperature.


Single dose vial formulation of a prostamide, used for the treatment of open angle glaucoma and ocular hypertension. Its formulation is preservative-free and avoids the need to store the product at a low temperature.


Topical corticosteroid of medium potency, formulated for the treatment of otic eczema. It is presented in single-dose containers, which makes its administration very comfortable and convenient in any situation.


Together we are stronger

Salvat’s sustainability depends on our ability to develop truly innovative products targeting important unmet needs. Our constant growth wouldn’t be possible without a large network of top-tier international partners. They assist us in identifying market needs and they know the key to success in every region.

Thanks to our partners, international sales already represent 40% of our business.


Salvat offers leading contract development services in ophthalmic, otic, nasal and oral formulations for pre-clinical, clinical and registration purposes.

– Pre-Formulation
– Formulation Development
– Analytical Development
– Clinical Supplies (including BFS)

Salvat’s Proprietary Technology Platforms:

– Ophthalmic and Otic Smart Nano-emulsions
– Nasal Smart Polymers
– Oral Multiparticulate Drug Delivery Systems



Operational excellence

We own three manufacturing sites. Our two Spanish sites are located in Esplugues de Llobregat (Barcelona) and Alcalá de Henares (Madrid). Our US site, in partnership with New Vision Pharmaceuticals, is located in Tamarac, Florida and is FDA approved. Each of our sites is equipped with the latest technology and complies with GMP regulations.


In addition to manufacturing for our own needs, we offer complete contract manufacturing services. Our contract manufacturing services are best suited for companies requiring support with the production of clinical and small commercial batches. As a privately-owned company we can ensure flexibility, adaptability, and operational excellence.

Available Technologies

Solids: Capsules, sachets, tablets, ODT, pellets, powder, granulation
Semisolids: Gels, creams
Liquids: Eye drops, solutions, suspensions, syrups, Blow-Fill-Seal
Packaging: Blister, ALU/ALU, STRIP

Blow-Fill-Seal technology expertise

We have over 10 years of experience in Blow-Fill-Seal technology, developing and manufacturing sterile products. BOTTELPACK® Blow-Fill-Seal is a modern and established technology that allows manufacturing with high sterility levels. A LDPE container is formed, filled with a liquid product and sealed in a continuous process without human intervention. The entire process is in a sterile enclosed area inside a machine.
This allows preservative free, single-dose packaging, in a sterile manufacturing process. All doses remain sterile until used, which contributes to increased regulation compliance.


Our new manufacturing site in Madrid

With the acquisition of Pharmaloop, Salvat expands its capacity in the manufacturing of solid and liquid products, and establishes the foundation for further expansion in sterile manufacturing.

Visit Pharmaloop website


Direct presence in Spain and Portugal

Since our foundation in 1955, we have commercialized our products in Spain through our own marketing & sales structure. Our direct presence has helped us build a strong reputation amongst doctors and pharmacists who continue to prescribe our brands nationwide.

Our sales and marketing team exceeds 100 professionals, all of them with vast market expertise.